Analysts expect Calidi Biotherapeutics, Inc. to report revenue of 0.00 for Q2 24, against a range of 0.00 to 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | |||||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Calidi Biotherapeutics, Inc. to report earnings per share of -4.22 for Q3 26, against a range of -4.48 to -3.96. The most recent reported quarter, Q2 26, came in at -2.94.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -124.80 | -51.84 | -34.56 | -31.84 | -35.36 | -9.12 | -6.88 | -2.94 | - | - | - | - | - | - | - | - | ||||||
| High Estimate | -142.02 | -64.26 | -25.85 | -27.13 | -24.54 | -24.43 | - | - | -3.96 | 22.77 | -27.69 | -28.97 | -20.42 | 7.81 | -25.17 | -33.76 | ||||||
| Low Estimate | -169.64 | -68.72 | -29.09 | -30.43 | -27.76 | -27.49 | - | - | -4.48 | 20.37 | -33.19 | -31.77 | -23.76 | 7.15 | -29.29 | -38.94 | ||||||
| Consensus Estimate | -155.83 | -66.49 | -27.47 | -28.78 | -26.15 | -25.96 | - | - | -4.22 | 21.57 | -30.44 | -30.37 | -22.09 | 7.48 | -27.23 | -36.35 |